P- gp- substrat Et in vitro- studie viser, at zonisamid er en svag hæmmer af P- gp (MDR1) med en IC50 på 267 µmol/ l, og zonisamid kan i teorien påvirke farmakokinetikken for lægemidler, der er P- gp- substrater.
P-gp substrate An in vitro study shows that zonisamide is a weak inhibitor of P-gp (MDR1) with an IC50 of 267 µmol/ L and there is the theoretical potential for zonisamide to affect the pharmacokinetics of drugs which are P-gp substrates.